The Board of Directors and the CEO reports the following for the fiscal year 2019. Unless otherwise stated, all amounts are reported in integers SEK (SEK). Data in parentheses refer to the previous year.
Strong fourth quarter with the first order for Efemia from a Swedish healthcare region
and distribution agreements for Norway, the Netherlands and Belgium.
TWELVE MONTHS (January–December 2019)
∞ The company’s sales amounted to 620 (41) KSEK.
∞ Other operating income amounted to 0 (17) KSEK.
∞ Work capitalised by the company for its own use amounted to 0 (427) KSEK.
∞ Operating costs amounted to 13,357 (9,795) KSEK.
∞ Result after tax amounted to -12,743 (-9,311) KSEK.
∞ Result per share amounted to -1.23 (-0.94) SEK.
∞ Cash and cash equivalents at the end of the period amounted to 2,606 KSEK.
∞ The board and the CEO propose that no dividend be paid for the financial year 2019-01-01–2019-12-31.
FOURTH QUARTER (October–December 2019)
∞ The company’s sales amounted to 372 (41) KSEK.
∞ Other operating income amounted to 0 (0) KSEK.
∞ Work capitalised by the company for its own use amounted to 0 (0) KSEK.
∞ Operating costs amounted to 4,150 (2,747) KSEK.
∞ Result after tax amounted to -3,783 (-2,706) KSEK.
∞ Result per share amounted to -0.37 (-0.26) SEK.
CEO Karin Bryder summarizes the quarter
In fourth quarter of 2019 we received the first order for Efemia from a Swedish healthcare region, and we were able to present market launches in Norway, the Netherlands and Belgium. At the same time, sales were initiated in Germany and the UK with a positive response from users, distributors and entities within the public healthcare sector. In addition to this, our Danish distributor Props & Pearls expanded its outreach and is now registered as distributor to 21 municipalities in the country, including Copenhagen. These advances meant that we could end 2019 in the best possible way. We are now looking forward to an incredibly exciting 2020, when we expect to achieve significant sales volumes and revenues while further accelerating the international expansion with Efemia. Focus will be on launches in additional European countries as well as planning our entry on the US market. To finance these efforts, we will carry out a preferential share issue with subscription period now in February, and my hope is that both existing and new shareholders choose to participate and join the company’s continued journey with the aim of taking Efemia across the Atlantic.